ProteAI™ harnesses physics-based artificial intelligence to design the next generation of protein therapeutics.
Contact Us
Platform Overview
The future of protein therapeutics requires a paradigm shift beyond data-driven pattern matching. ProteAI™ is a pioneering design platform that uniquely integrates artificial intelligence with the first principles of biophysics. We are developing next-generation AI that is trained to comprehend the fundamental physical laws governing protein folding and interactions. This enables our platform to move beyond conventional interpolation and extrapolation from existing data, empowering the intelligent de novo creation and multi-parameter optimization of novel, developable protein therapeutics across any modality, from antibodies to engineered scaffolds.
Disruptive Technology
Excellent Team
Diversified Pipeline
Customized Solutions
Platform Core
At the heart of ProteAI™ is a physics-grounded AI engine and a tightly closed design-validation loop.
Platform Advantages
Principle-Driven Discovery
Unlike data-limited models, ProteAI’s first-principles foundation allows it to venture into unexplored sequence territory. It discovers high-potential, optimizable molecules, including those with novel epitopes or functions that conventional methods often miss, thereby de-risking and enriching your pipeline.
Modality-Agnostic Versatility
Our platform is not confined to any specific therapeutic format. This inherent flexibility means it can be employed to design a wide range of protein-based therapeutics, including antibodies, VHHs, mini-proteins, cytokines, and more. This broad compatibility accelerates innovation across diverse therapeutic areas, providing a single, powerful engine for all your biologics discovery programs.
Concurrent Multi-Parameter Optimization
ProteAI intelligently balances multiple critical attributes in a single design cycle. Simultaneously optimize for target affinity, specificity, stability, developability, and immunogenicity risk to arrive at superior, development-ready candidates faster. The platform enables free insertion and deletion of amino acids, allowing for a broader exploration of the optimal protein sequence space.
Platform Application
Create fully novel, functional protein sequences from scratch. Ideal for targeting novel epitopes, designing against targets with limited structural data, or pioneering entirely new therapeutic protein classes.
Rapidly transform early hits into optimized leads. Improve affinity, stability, and expression while mitigating developability issues, compressing years of iterative optimization into significantly shorter cycles.
Re-imagine protein scaffolds. Engineer new binding sites or functions into stable frameworks (e.g., Fc regions) to create bespoke multi-specific or cell-engaging therapeutics, turning strategic concepts into tangible molecules.
Pipeline
| Projects | Therapy Types | Target | Indication | Discovery | Preclinical | IND | Phase I | Phase II | Phase III |
|---|---|---|---|---|---|---|---|---|---|
| PTA005 | Monoclonal Antibody | PD-L1 | Solid Tumors | ||||||
| PTA012 | Bispecific Antibody | HER2 x EGFR | Solid Tumors | ||||||
| PTA024 | Immunocytokine | PD-1 / 1L-18V | Solid Tumors | ||||||
| PTA019 | Monoclonal Antibody | ALK7 | Fibrotic Diseases | ||||||
Contact Us
FAQs
Q1: What makes ProteAI™ different from other AI protein design platforms?
Q2: How do you validate the AI's designs?
Q3: What level of control do we have over the design process?
Q4: How does ProteAI™ handle immunogenicity risk in de novo designs?
Q5: Can we collaborate if we only have a target idea, not a lead molecule?
ProteAI™ platform transforms the fundamental principles of biophysics into intelligently designed, next-generation protein therapeutics, unlocking novel targets and accelerating development with superior precision.
Copyright © 2026 Protheragen. All rights reserves.